(Reuters) -Caris Life Sciences’ shares jumped nearly 29% in their New York debut on Wednesday, fetching the cancer diagnostic firm a valuation of $7.66 billion and signaling a growing investor appetite for new listings in 2025.
The shares opened at $27 apiece, compared with their offer price of $21, at which Caris Life sold 23.5 million shares to raise $494.1 million on Tuesday.
U.S. IPO market activity has shown signs of a sustained revival with a few fresh listings such as Circle <CRCL.N> and Chime getting overwhelming support from investors in the past couple of weeks, after a slow start to the year.
Shares of insurance tech firm Slide jumped nearly 24% in their Nasdaq debut on Wednesday as well.
(Reporting by Pritam Biswas in Bengaluru; Editing by Shinjini Ganguli and Maju Samuel)
Brought to you by www.srnnews.com
